More recently, similar SMO inhibitors such as Vismodegib [99, 100], Sonidegib [100, 101] and Erismodegib [99, 102] are under-development in clinical trials for patients with AML and MDS, in combination with chemotherapies such as Azacytidine, a hypomethylating agent. Here, SMO is linked to acute myeloid leukemia.